PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 2, 2026Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma0 citationsOpen Access

Značajna supresija aldosterona deksametazonom

View Full Paper
BMBojan MarkovićMSMirjana StojkovićNJNata Joksimović

Key Result

Despite significant biochemical suppression of aldosterone by dexamethasone suggesting glucocorticoid-remediable aldosteronism, genetic testing excluded the CYP11B1/CYP11B2 chimeric gene.

Key Points

  • The aim is to highlight the role of dexamethasone in identifying glucocorticoid-remediable aldosteronism (GRA).
  • Presented a case of a young female with hypertension diagnosed early in adulthood.
  • Dexamethasone suppression test showed significant aldosterone suppression.
  • Genetic testing was indicated after suspicions of GRA arose.
  • Dexamethasone led to significant suppression of aldosterone levels.
  • Genetic testing excluded the presence of CYP11B1/CYP11B2 hybrid gene despite biochemical findings suggesting GRA.
  • Emphasizes the importance of genetic confirmation in suspected GRA cases, especially in younger patients with familial history.

Study Design

Type

Case Report (n=1)

Structured PICO

P
Population
1 female patient with long-standing arterial hypertension diagnosed in early adulthood, elevated basal aldosterone, and borderline aldosterone/plasma renin activity ratio
I
Intervention
Dexamethasone suppression test and genetic testing for CYP11B1/CYP11B2 chimeric gene
O
Outcome
Diagnosis of Glucocorticoid remediable aldosteronism (GRA) via genetic confirmation

This case highlights the necessity of genetic confirmation for diagnosing Glucocorticoid remediable aldosteronism, as biochemical suppression by dexamethasone alone is insufficient.

Abstract

ACTH zavisni aldosteronizam (Glucocorticoid remediable aldosteronism - GRA) predstavlja retku, autozomno-dominantnu formu primarnog aldosteronizma koja nastaje usled himerizacije gena CYP11B1/CYP11B2 i dovodi do povećane produkcije aldosterona. Supresija aldosterona deksametazonom može ukazivati na ovaj poremećaj, dok genetska analiza ostaje zlatni standard dijagnostike. Prikazana je pacijentkinja sa dugogodišnjom arterijskom hipertenzijom koja je dijagnostikovana u ranoj odrasloj dobi. Zabeležen je povišen bazalni aldosteron uz granične vrednosti odnosa aldosteron/plazma reninska aktivnost. Radiološka dijagnostika nije ukazala na morfološke promene nadbubrežnih žlezda. Učinjeni su potvrdni testovi (kaptoprilski test, infuzioni test, DST). Deksametasonski supresioni test pokazao je značajnu supresiju aldosterona, što je pobudilo sumnju na GRA i dovelo do indikacije za genetsko testiranje. Diferencijalna dijagnoza hiperaldosteronizma obuhvata adenom, hiperplaziju, ektopičnu produkciju i genetske oblike kao što je GRA. Biohemijska supresija aldosterona može ukazivati na familijarni oblik aldosteronizma tip I, ali nije dovoljna za potvrdu dijagnoze. Genetska analiza omogućava definitivno razlikovanje GRA od drugih oblika primarnog aldosteronizma. Kod pacijentkinje je, uprkos biohemijskim nalazima koji su delimično sugerisali GRA, genetskim testiranjem isključeno prisustvo CYP11B1/CYP11B2 himernog gena. Ovaj slučaj ukazuje na važnost genetske potvrde kod sumnje na GRA, naročito u mlađih bolesnika sa opterećenjem u porodičnoj anamnezi.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Marković et al. (2026) conducted a case report in Primary aldosteronism / Suspected Glucocorticoid-remediable aldosteronism (n=1). Dexamethasone suppression test and genetic testing was evaluated on Presence of CYP11B1/CYP11B2 chimeric gene. Despite significant biochemical suppression of aldosterone by dexamethasone suggesting glucocorticoid-remediable aldosteronism, genetic testing excluded the CYP11B1/CYP11B2 chimeric gene.

synapsesocial.com/papers/6a1e72e830b38c64201b6266https://doi.org/10.5937/mgiszm2600108m
Ask AI
Helpful
Bookmark
Share
View Full Paper